Literature DB >> 9359023

Classification, diagnosis and treatment of vascular dementia.

S Konno1, J S Meyer, Y Terayama, G M Margishvili, K F Mortel.   

Abstract

Vascular dementia (VAD) is considered to be the second most common cause of dementia in Europe and the US. In Asia and many developing countries, it is more common than dementia of the Alzheimer's type (DAT). VAD is the most preventable form of dementia associated with later life. The pathogenesis of VAD is multifactorial, and it represents a heterogeneous, not a homogeneous, clinical entity. Classification of VAD by pathogenesis is important for its prevention and treatment. Control of the risk factors for VAD reduces its incidence and stabilises or improves cognitive performance following stroke. Proper diagnostic evaluation of VAD requires: (i) a well defined quantitative assessment of the cognitive deficits present; (ii) assessment of risk factors for stroke; (iii) identification of cerebral vascular lesions by history, neurological examination and neuroimaging; (iv) exclusion of other causes of dementia; (v) establishment of a positive diagnosis of possible, probable or definite VAD versus DAT or mixed VAD/DAT; and (vi) identification of the temporal relationship between cognitive deficits and cerebral vascular lesions. VAD can be subdivided into 8 major types, as follows: (i) multi-infarct dementia secondary to large cerebral emboli [type 1]; (ii) strategically placed infarctions causing dementia [type 2]; (iii) multiple subcortical lacunar lesions secondary to atherosclerosis or degenerative arteriolar changes [type 3]; (iv) Binswanger's disease (arteriosclerotic subcortical leukoencephalopathy) [type 4]; (v) mixtures of types 1, 2 and 3 [type 5]; (vi) haemorrhagic lesions causing dementia [type 6]; (vii) subcortical dementia secondary to hereditary factors (type 7); and (viii) mixtures of DAT and VAD (type 8). Treatment is dictated by the pathogenetic subtype of VAD that is present.

Entities:  

Mesh:

Year:  1997        PMID: 9359023     DOI: 10.2165/00002512-199711050-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  75 in total

1.  Atrial fibrillation and dementia in a population-based study. The Rotterdam Study.

Authors:  A Ott; M M Breteler; M C de Bruyne; F van Harskamp; D E Grobbee; A Hofman
Journal:  Stroke       Date:  1997-02       Impact factor: 7.914

Review 2.  Status of risk factors for dementia associated with stroke.

Authors:  P B Gorelick
Journal:  Stroke       Date:  1997-02       Impact factor: 7.914

3.  The clinical diagnosis of Alzheimer's disease.

Authors:  J P Wade; T R Mirsen; V C Hachinski; M Fisman; C Lau; H Merskey
Journal:  Arch Neurol       Date:  1987-01

4.  The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases.

Authors:  M C Tierney; R H Fisher; A J Lewis; M L Zorzitto; W G Snow; D W Reid; P Nieuwstraten
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

5.  15-year longitudinal study of blood pressure and dementia.

Authors:  I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg
Journal:  Lancet       Date:  1996-04-27       Impact factor: 79.321

6.  Cerebral blood flow changes in benign aging and cerebrovascular disease.

Authors:  T G Shaw; K F Mortel; J S Meyer; R L Rogers; J Hardenberg; M M Cutaia
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese.

Authors:  N Watanabe; Y Imai; K Nagai; I Tsuji; H Satoh; M Sakuma; H Sakuma; J Kato; N Onodera-Kikuchi; M Yamada; F Abe; S Hisamichi; K Abe
Journal:  Stroke       Date:  1996-08       Impact factor: 7.914

Review 8.  The clinical diagnosis of vascular dementia.

Authors:  A Wallin; K Blennow
Journal:  Dementia       Date:  1994 May-Aug

9.  Morphometry of structural preservation of tunica media in aged and hypertensive human intracerebral arteries.

Authors:  N Masawa; Y Yoshida; T Yamada; T Joshita; S Sato; B Mihara
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

10.  Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction.

Authors:  A J Azar; P J Koudstaal; A R Wintzen; P F van Bergen; J J Jonker; J W Deckers
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

View more
  6 in total

Review 1.  Smoking and increased Alzheimer's disease risk: a review of potential mechanisms.

Authors:  Timothy C Durazzo; Niklas Mattsson; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2014-06       Impact factor: 21.566

2.  Subcortical ischemic vascular dementia: assessment with quantitative MR imaging and 1H MR spectroscopy.

Authors:  A A Capizzano; N Schuff; D L Amend; J L Tanabe; D Norman; A A Maudsley; W Jagust; H C Chui; G Fein; M R Segal; M W Weiner
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

3.  Neurobiology of vascular dementia.

Authors:  Ana-Maria Enciu; Stefan N Constantinescu; Laurenţiu M Popescu; Dafin F Mureşanu; Bogdan O Popescu
Journal:  J Aging Res       Date:  2011-08-17

4.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?

Authors:  Nikolaos Dagres; Tze-Fan Chao; Guilherme Fenelon; Luis Aguinaga; Daniel Benhayon; Emelia J Benjamin; T Jared Bunch; Lin Yee Chen; Shih-Ann Chen; Francisco Darrieux; Angelo de Paola; Laurent Fauchier; Andreas Goette; Jonathan Kalman; Lalit Kalra; Young-Hoon Kim; Deirdre A Lane; Gregory Y H Lip; Steven A Lubitz; Manlio F Márquez; Tatjana Potpara; Domingo Luis Pozzer; Jeremy N Ruskin; Irina Savelieva; Wee Siong Teo; Hung-Fat Tse; Atul Verma; Shu Zhang; Mina K Chung; William-Fernando Bautista-Vargas; Chern-En Chiang; Alejandro Cuesta; Gheorghe-Andrei Dan; David S Frankel; Yutao Guo; Robert Hatala; Young Soo Lee; Yuji Murakawa; Cara N Pellegrini; Claudio Pinho; David J Milan; Daniel P Morin; Elenir Nadalin; George Ntaios; Mukund A Prabhu; Marco Proietti; Lena Rivard; Mariana Valentino; Alena Shantsila
Journal:  J Arrhythm       Date:  2018-03-23

5.  Non-vitamin K Antagonist Oral Anticoagulants and Cognitive Impairment in Atrial Fibrillation: Insights From the Meta-Analysis of Over 90,000 Patients of Randomized Controlled Trials and Real-World Studies.

Authors:  Chi Zhang; Zhi-Chun Gu; Long Shen; Mang-Mang Pan; Yi-Dan Yan; Jun Pu; Xiao-Yan Liu; Hou-Wen Lin
Journal:  Front Aging Neurosci       Date:  2018-10-02       Impact factor: 5.750

Review 6.  Risk of cognitive impairment with non-vitamin K antagonist oral anticoagulants in atrial fibrillation: Protocol for a systemic review of randomized controlled trials and real-world studies.

Authors:  Long Shen; Chi Zhang; Zhi-Chun Gu; Hou-Wen Lin; Xiao-Yan Liu; Jun Pu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.